Related Experiment Videos
[Long-term course in differentiated thyroid gland carcinoma]
Schweizerische Medizinische Wochenschrift
|November 28, 1992
Summary
Differentiated thyroid carcinoma patients show significant long-term recurrence rates. Total thyroidectomy and radioiodine treatment are crucial for preventing recurrence and improving survival in differentiated thyroid cancer.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Context:
- Differentiated thyroid carcinoma (DTC) management involves long-term follow-up.
- Understanding factors influencing residual disease and recurrence is critical for patient outcomes.
Purpose:
- To analyze long-term outcomes in 545 differentiated thyroid carcinoma patients.
- To identify risk factors for residual tumor and tumor recurrence.
- To evaluate the impact of treatment modalities on differentiated thyroid carcinoma prognosis.
Summary:
- Long-term follow-up (mean 8.1 years) of 545 DTC patients revealed 72% papillary and 52% follicular carcinoma patients remained tumor-free.
- Tumor recurrences occurred in 22% (papillary) and 31% (follicular) cases, with late recurrences observed up to 27 years.
- Mortality was equally attributed to residual and recurrent disease; total thyroidectomy and postoperative radioiodine treatment significantly reduced recurrence risk.
Impact:
- Treatment strategies significantly influence differentiated thyroid carcinoma mortality.
- Early radioiodine ablation of thyroid remnants is key to managing recurrent disease.
- Optimized radioiodine dosing and reduced usage for follow-up demonstrate a safe and effective approach.